Waksal back to deal-making mode, snags Three Rivers for $100M

The Wall Street Journal broke the story this morning that Sam Waksal's Kadmon Pharmaceuticals has struck a deal to buy Three Rivers Pharmaceuticals for $100 million as he promises to take what he accomplished at ImClone and take "it to the next step to build a 21st century biotech company."

Kadmon has raised $200 million from a group of investors who believe that Waksal, who spent five years behind bars for his notorious role in a clumsy insider trading scandal, can once again build a biotech company into a valuable commodity. Kadmon is focusing on new therapies for cancer and infectious diseases and Three Rivers, which already markets hepatitis C treatments, provides an operations and commercialization base that can be used to build the company into a fully integrated biotech outfit.

"Three Rivers is at an inflection point," Waksal told the Journal. Later, in a statement, he added: "Kadmon is building a new paradigm for bringing pioneering medicines to market more rapidly and cost effectively. This includes the simultaneous execution of a dual strategy, combining an operating commercial business with novel compounds at various stages of clinical development."

- here's the release
- read the story from the Wall Street Journal

ALSO: Sam Waksal - Notorious Names in Biopharma

Suggested Articles

The platform, which is in use at companies including Agios, enables researchers to simultaneously detect DNA and protein changes in single cells. 

As Urovant gears up for the launch of vibegron, its overactive bladder treatment, it is pushing the same drug through the clinic in other indications.

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.